Adaptive Biotechnologies Corporation
ADPT
$15.68
-$0.44-2.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 276.98M | 252.75M | 205.22M | 189.53M | 178.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 276.98M | 252.75M | 205.22M | 189.53M | 178.96M |
| Cost of Revenue | 71.36M | 63.43M | 62.43M | 64.97M | 72.08M |
| Gross Profit | 205.62M | 189.33M | 142.79M | 124.56M | 106.88M |
| SG&A Expenses | 167.27M | 162.87M | 159.25M | 156.10M | 157.57M |
| Depreciation & Amortization | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 334.10M | 330.94M | 326.33M | 325.71M | 334.30M |
| Operating Income | -57.12M | -78.19M | -121.11M | -136.19M | -155.34M |
| Income Before Tax | -59.46M | -79.60M | -121.24M | -141.89M | -159.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.46 | -79.60 | -121.24 | -141.89 | -159.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -42.00K | -17.00K | 8.00K | 55.00K | 103.00K |
| Net Income | -59.50M | -79.61M | -121.23M | -141.84M | -159.49M |
| EBIT | -57.12M | -78.19M | -121.11M | -136.19M | -155.34M |
| EBITDA | -39.29M | -60.10M | -102.84M | -117.41M | -136.09M |
| EPS Basic | -0.39 | -0.53 | -0.81 | -0.96 | -1.09 |
| Normalized Basic EPS | -0.25 | -0.34 | -0.52 | -0.58 | -0.66 |
| EPS Diluted | -0.40 | -0.54 | -0.82 | -0.96 | -1.09 |
| Normalized Diluted EPS | -0.25 | -0.35 | -0.52 | -0.58 | -0.66 |
| Average Basic Shares Outstanding | 606.84M | 601.39M | 596.47M | 591.80M | 588.40M |
| Average Diluted Shares Outstanding | 617.57M | 612.12M | 596.47M | 591.80M | 588.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |